Skip to content

Study · Not a test of the peptide alone · 2021

3 results

Are glucagon-like peptide 1 analogues effective and safe in severe COVID-19 patients with type 2 diabetes?-a case report.

Chen S, Lin W, Wen J, Xie B, Chen L, Chen G

Annals of palliative medicine5 Jan 2021Cited by 2 (Europe PMC)

PMID33440950 (opens in a new tab)DOI10.21037/apm-20-1982 (opens in a new tab)PepBankPUB-33440950
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome

    In a 65-year-old man with type 2 diabetes and severe COVID-19, a regimen of liraglutide with hydroxychloroquine and abidol was followed by blood glucose under control.

    In plain wordsIn one man with diabetes and severe COVID-19, blood sugar was controlled after treatment including liraglutide and two other drugs. Case report.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedBlood glucose control
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    After treatment, the patient's blood glucose was under control
    2 context sentences
    Summary · context
    In this case, we described A 65-year-old male with hypertension and diabetes was diagnosed with severe COVID-19, he took liraglutide at doses ranging from 0.8 to 1.8 mg.
    Summary · context
    Hydroxychloroquine sulfate and abidol were used to antivirus and supportive treatment were used simultaneously during hospitalization.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneCase report or seriesSafety outcome

    In a 65-year-old man with type 2 diabetes and severe COVID-19, liver function, renal function, white blood cells and lymphocytes were normal after a regimen of liraglutide with hydroxychloroquine and abidol.

    In plain wordsIn one man with diabetes and severe COVID-19, liver, kidney and blood cell tests were normal after treatment that included liraglutide and two other drugs.

    Peptide
    Liraglutide
    Outcome
    No significant changeLiver and kidney function and blood counts
    Study

    n = 1

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    and his liver function, renal function, white blood cells, lymphocytes and other indicators were normal
    2 context sentences
    Summary · context
    In this case, we described A 65-year-old male with hypertension and diabetes was diagnosed with severe COVID-19, he took liraglutide at doses ranging from 0.8 to 1.8 mg.
    Summary · context
    Hydroxychloroquine sulfate and abidol were used to antivirus and supportive treatment were used simultaneously during hospitalization.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome

    In a 65-year-old man with type 2 diabetes and severe COVID-19, chest CT improved after a regimen of liraglutide with hydroxychloroquine and abidol.

    In plain wordsIn one man with diabetes and severe COVID-19, the chest scan improved after treatment including liraglutide and two other drugs. Case report.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedChest CT
    Study

    n = 1

    Outcome group
    Infection and antimicrobial activity · Respiratory

    Source sentences

    Summary
    and chest CT also improved.
    2 context sentences
    Summary · context
    In this case, we described A 65-year-old male with hypertension and diabetes was diagnosed with severe COVID-19, he took liraglutide at doses ranging from 0.8 to 1.8 mg.
    Summary · context
    Hydroxychloroquine sulfate and abidol were used to antivirus and supportive treatment were used simultaneously during hospitalization.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.